CSRP2 and glioblastoma: Next, we treated GBM cells stably overexpressing CSRP2 with MTO and found that MTO treatment significantly inhibited cell proliferation (Fig. 8B, C), colony formation (Fig. 8D, E), migration (Fig. 8F, G), and invasive ability (Fig. 8H, I), and increased cell apoptosis (Fig. 8J, K).